Clinical Trials Browser

Phase 2 × INDUSTRY × tisagenlecleucel × Clear all

Burkitt Lymphoma, Neoplasm, Residual

NCT03568461 2025-10-07

ELARA

Phase 2 Completed

98 enrolled 9 charts 2 FDA

Lymphoid

Lymphoma, Follicular, Recurrence

NCT03610724 2024-06-20

BIANCA

Phase 2 Completed

34 enrolled 19 charts

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02445248 2024-04-18

JULIET

Phase 2 Completed

115 enrolled 22 charts 2 FDA

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02435849 2024-02-13

ELIANA

Phase 2 Completed

80 enrolled 39 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04156659 2023-03-09

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Phase 2 Withdrawn

Lymphoid

Burkitt Lymphoma

NCT04225676 2023-01-30

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Phase 2 Terminated

5 enrolled 8 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04456023 2022-03-02

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Phase 2 Withdrawn

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02228096 2020-11-23

ENSIGN

Phase 2 Completed

75 enrolled 41 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

CASSIOPEIA

ELARA

BIANCA

JULIET

ELIANA

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

ENSIGN